Polygone Logo White

As we embark on a new era of genomics, genetic testing

has become increasingly significant in enhancing

individualised health care. Tests to identify susceptibilities

to common diseases like cancer and diabetes will soon

provide a guide to preventive care. 

The potential benefits of identifying a patient’s polygenic

risk score and storing their blood/DNA samples is that

it can be used to predict their future susceptibility to

disease. In addition to early diagnosis of rare and chronic

diseases, it can also be used to identify safer and more

effective drug therapy based on their DNA response to

prescribed medication.

Polygene has partnered with DNAlysis to deliver the gold

standard of quality genetic testing and validated results.

Combining pharmacology (the science of drugs) and

genomics (the study of genes and their functions),

Polygene is dedicated to the testing and understanding

of how a patient’s genes will affect their response to

medication, thereby enabling doctors to make precision

treatment decisions for enhanced efficacy. 



It’s not just intelligent, it’s gene-ius  

Nuno Vaz Dos Ramos

  • Chief Technology Officer at BrandMed
  • Oversees the development of a comprehensive risk and disease management platform for patients with Hypertension, Diabetes, Asthma and COPD. Awarded 2014 Innovation Prize by Microsoft and the Israeli Trade Commission for the design of a hospital readmission programme using  wearable devices